Primary aims
Aim 1: To determine whether measures of essential fatty acid (EFA) membrane composition predict symptom improvement during selective serotonin reuptake inhibitor (SSRI) treatment of major depressive disorder.
Aim 2: To determine whether augmentation with the EFA eicosapentaenoic acid